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Background: Despite overall progress in treatment of autoimmune diseases, patients with systemic lupus
erythematosus (SLE) experience many inflammatory symptoms representing an unmet medical need. This
study aimed to create a conceptual model of the humanistic and economic burden of SLE, and review the
patient-reported outcomes (PROs) used to measure such concepts in SLE clinical trials.
Methods: A conceptual model for SLE was developed from structured review of published articles from 2007 to
August 2013 identified from literature databases (MEDLINE, EMBASE, PsycINFO, EconLit) plus other sources
(PROLabels, FDA/EMA websites, Clinicaltrials.gov). PROs targeting key symptoms/impacts were identified from the
literature. They were reviewed in the context of available guidance and assessed for face and content validity and
psychometric properties to determine appropriateness for use in SLE trials.
Results: The conceptual model identified fatigue, pain, cognition, daily activities, emotional well-being, physical/
social functioning and work productivity as key SLE concepts. Of the 68 articles reviewed, 38 reported PRO data.
From these and the other sources, 15 PROs were selected for review, including SLE-specific health-related quality
of life (HRQoL) measures (n = 5), work productivity (n = 1), and generic measures of fatigue (n = 3), pain (n = 2),
depression (n = 2) and HRQoL (n = 2). The Functional Assessment of Chronic Illness Therapy - Fatigue Scale
(FACIT-Fatigue), Brief Pain Inventory (BPI-SF) and LupusQoL demonstrated the strongest face validity, conceptual
coverage and psychometric properties measuring key concepts in the conceptual model. All PROs reviewed,
except for three Lupus-specific measures, lacked qualitative SLE patient involvement during development. The
Hospital Anxiety and Depression Scale (HADS), Short Form [36 item] Health Survey version 2 (SF-36v2), EuroQoL
5-dimensions (EQ-5D-3L and EQ-5D-5L) and Work Productivity and Activity Impairment Questionnaire: Lupus
(WPAI:Lupus) showed suitability for SLE economic models.
Conclusions: Based on the identification of key symptoms and impacts of SLE using a scientifically sound
conceptual model, we conclude that SLE is a condition associated with high unmet need and considerable burden
to patients. This review highlights the availability and need for disease-specific and generic patient-reported
measures of relevant domains of disease signs and symptoms, HRQoL and work productivity, providing useful
insight for SLE clinical trial design.
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Systemic lupus erythematosus (SLE) is a heterogeneous,
inflammatory, multisystem autoimmune disease. Estimates
of overall prevalence rates (per 100,000) vary worldwide,
ranging from 4–45 in Asia-Pacific countries [1], to 52–150
in the USA [2,3]. The prevalence of SLE is greater in non-
white racial groups [2] and the disease affects women more
frequently than men [4]. SLE is associated with a substan-
tial economic burden, with direct costs per patient-year
ranging from $3,735 to $14,410 [5].
There is a large variation in SLE associated symptoms
and the condition is often complicated by flares (exacer-
bations) of varying severity and subsequent remissions
[6]. A recent international consensus working group de-
fined a flare as “a measurable increase in disease activity
in one or more organ systems involving new or worse
clinical signs and symptoms and/or laboratory measure-
ments” [7].
Patients with active SLE experience musculoskeletal
and mucocutaneous manifestations, including joint pain
and swelling, skin rash and fatigue [8]. Frequently affected
joints include the fingers, hands, wrists and knees, with
some patients developing secondary osteoarthritis [8]. In
addition to joint inflammation, internal organ involvement
can be of greater concern when considering patients’ prog-
nosis, with SLE often affecting the heart, lungs, blood ves-
sels, liver, kidneys and nervous system [8,9]. Overall these
symptoms and manifestations can contribute to a substan-
tially reduced health-related quality of life (HRQoL) [10].
It is not possible to assess many of the symptoms and
treatment effects associated with SLE using objective clin-
ical measures alone. Regulatory bodies and healthcare deci-
sion makers recognise the importance of also capturing the
patient perspective in clinical trials by using validated and
reliable patient-reported outcome (PRO) measures [11-13].
The U.S. Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) have released guid-
ance which highlights the importance of measuring fatigue
in clinical trials in SLE [14,15] (although the FDA does not
necessarily consider existing measures of fatigue to be ad-
equate), and the EMA also strongly recommends the con-
sideration of the impact of SLE on patients’ HRQoL [15].
In 1999 an Outcome Measures in Rheumatology group
(OMERACT) performed a review of outcome measures
that have been used in SLE trials and made recommenda-
tions regarding the most important domains to assess, and
the most appropriate instruments to do so [16,17]. How-
ever, as it has been a number of years since that review,
there is value in a more up to date review of the literature
which identifies relevant concepts for measurement and
the adequacy of existing measures to assess those concepts.
In particular, no disease-specific measures of health status
or disability were identified at that time. An understanding
of the symptoms and their impact on patients’ daily lives,the economic burden and the PRO measures available, will
help researchers and clinicians evaluate the efficacy and
impact of interventions.
The objectives of this research were twofold. The ob-
jective of the first stage of this research was to review
and describe the symptoms and impact concepts of SLE
from the patient’s perspective by means of a conceptual
model. This included an overview of the economic burden
of SLE. Based on development of the conceptual model,
the objective was then to review existing PRO measures
for suitability in clinical trials of SLE, in terms of their
content validity, face validity and psychometric properties.
Methods
A structured literature review was conducted to estab-
lish the humanistic and economic burden with respect
to the key symptoms and their impact, and the PROs
available to measure these. Methods were in line with
recognised international guidelines for the conduct and
reporting of literature reviews [18,19]. The findings from
the literature review informed the development of a
conceptual model that was used to assess whether the
selected PRO measures target the key symptoms and im-
pacts of SLE in accordance with the EMA and FDA
PRO guidance [11,12].
Data sources and searches
Literature searches were conducted in MEDLINE, EM
BASE, PsycINFO and EconLit, limited to humans, English
language and articles published between 2007 and 2013.
The search was conducted on 1st August 2013.
Inclusion and exclusion criteria
Journal articles (excluding conference abstracts, disserta-
tions and book chapters) containing the keywords in the
title and/or abstract were included. Articles with an
SLE-related clinical search term and at least one of the
humanistic or economic search terms were selected.
Search terms included SLE clinical terms (systemic
lupus erythematosus, SLE, lupus nephritis, LN) plus out-
comes research terms (health-related quality of life,
quality of life, patient burden, patient impact, burden of
illness, symptom, activities of daily living, patient reported
outcome, patient related outcome, PRO, questionnaire,
fatigue, physical function, emotion, mood) or economic
terms (cost OR cost utility, cost of illness, healthcare cost,
economic burden, economic impact, resource use, hospi-
talisation, productivity, expenditure, direct costs, indirect
costs, economic, cost minimisation, burden of illness, cost
effectiveness).
Screening process and data extraction
Two researchers screened and checked all the abstracts
for eligibility and suitability in line with the Centre for
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lected for review were based on consensus opinion. Any
disagreement in the selection of articles was resolved by
the lead researcher who performed a final, independent
review of titles and abstracts. The selected articles were
categorised into qualitative studies reporting burden from
the patient perspective and articles reporting humanistic
and economic burden data. Literature documenting quan-
titative methods was also reviewed to further understand
the symptoms of SLE, the impact on patients’ HRQoL and
to support the conceptual model. Study characteristics
from the selected articles were extracted.
Development of the conceptual model of systemic lupus
erythematosus
A conceptual model of the humanistic and economic
burden of SLE was developed on the basis of the review
of qualitative studies [20]. A conceptual model can help
identify themes, describe the patient burden concepts
and their interrelationships and provide the rationale for
PRO measures of interest [11,21]. For the purposes of
this study, a conceptual model for SLE provided the the-
oretical basis for the review and evaluation of the con-
tent validity of the selected PRO measures. The model
was then compared with an existing SLE conceptual
model developed by Gallop et al. [22] in 2012.
Review of the patient-reported outcome measures for
systemic lupus erythematosus
A subset of the PRO measures identified in the literature
search were selected for in-depth review. Selection of in-
struments for in-depth review was based on likelihood
of meeting the FDA guidance and relevance of concep-
tual coverage, based on review of the abstract and initial
review of the PRO. Searches of PROQOLID, PROLabels,
FDA/EMA websites, Clinicaltrials.gov and reimburse-
ment agencies’ websites (e.g. National Institute of Health
and Care Excellence (NICE, UK) and the Institute for
Quality and Efficiency in Healthcare (IQWIG, Germany))
were conducted when either no relevant PRO that mea-
sured a key concept could be identified from the literature,
or when expert opinion suggested the use of alternative
PROs. Other PRO measures were only included in the re-
view if the PRO was developed or validated in patients
with SLE, had been previously used in a SLE population
and/or if there was evidence of normative data available
for comparison. Articles in the literature search that re-
ported PRO data were categorised according to the type
of PRO measure included in each study. The categories
were largely based on the key concepts identified in the
conceptual model.
Each PRO was reviewed for appropriateness for clin-
ical trials in patients with SLE in terms of content valid-
ity, face validity and psychometric properties, in linewith regulatory guidance for the evaluation of PRO mea-
sures [11,12]. Content validity was assessed by the cover-
age level of the concepts within the conceptual model
[11,12]. The face validity of each PRO measure was deter-
mined by the acceptability and appropriateness of item
wording, recall period and response options to patients
with SLE. The level of qualitative research involved in de-
veloping each PRO was also assessed, acknowledging the
value of input from the target patient population. The psy-
chometric properties (validity, reliability and ability to de-
tect change) of each PRO for an SLE population were also
assessed in line with FDA regulatory guidance for the de-
velopment and validation of PROs [11,23].
Results
Findings from the literature search
The literature search identified a total of 1,754 publica-
tions. Of these, 687 articles met the inclusion criteria and
the full articles were retrieved. A review of these identified
30 articles containing data on the economic burden of
SLE. These were used to describe the economic burden in
the conceptual model. The remaining 38 articles were re-
lated to patient-reported symptoms, impacts and burden
in patients with SLE.
Conceptual model of systemic lupus erythematosus
Of the 38 articles that included patient-reported data, six
were qualitative articles [22,24-28] and 32 were quantita-
tive articles. The resulting conceptual model shows the
symptoms and impacts identified as key concepts related
to SLE (Figure 1).
Fatigue and pain were identified as two of the most
important and frequent symptoms for patients with SLE
[24-26,29-32] (Figure 1). Specifically, patients describe men-
tal and physical symptoms of fatigue including impacts on
social life [24], emotional wellbeing [24,33], physical func-
tioning [22,24], sleep [31,34-36] and the ability to complete
daily tasks and leisure activities [27,28]. Important cognitive
symptoms include being “unable to think clearly” [22] and
memory loss [22]. Other SLE symptoms include skin rash
[27,37], weight gain [24,27] and hair loss [25,27].
Symptoms impact all areas of HRQoL, with detrimen-
tal consequences observed in the physical, emotional
and social functioning of SLE patients, as well as in their
working life (Figure 1). In terms of the impact on emo-
tional wellbeing, patients with SLE frequently feel sad,
depressed, angry and demoralised [22,24,25,30,37,38]. In
particular, patients feel embarrassed [24,25,39] or self-
conscious, or they lack self-esteem, primarily because of
the change in their appearance (such as hair loss and skin
manifestations) [22,26]. Patients fear their disease worsen-
ing, and experience anxiety or stress related to the symp-
toms and the unpredictability of SLE [27,30,37,38]. Many
also experience feelings of frustration and a lack of 1)
Figure 1 Systemic lupus erythematosus conceptual model.
Holloway et al. Health and Quality of Life Outcomes 2014, 12:116 Page 4 of 14
http://www.hqlo.com/content/12/1/116confidence, 2) independence, 3) control over one’s life and
4) belonging [40].
SLE has a significant negative impact on patients’ phys-
ical functioning, such as walking difficulty and other mobil-
ity problems [10,22,26,41] (Figure 1). This affects various
daily activities including opening jars and moving heavy
objects [41], shopping [22], doing laundry [26], getting
dressed [26] and caring for their children [24,26]. Wider
impacts on social functioning and working life are also re-
ported [29,40]. Specifically, patients have difficulty main-
taining family and sexual relationships [24,26,37]. SLE also
impacts negatively on patients’ career progression [25], ab-
sence from work [22], difficulty concentrating at work or
study [22,26,32] and their choice of work [26,27].
The conceptual model presented in this paper suggests
that patients use various coping mechanisms for the
unpredictability of flares, including 1) seeking and using
information, 2) seeking emotional and practical help via
the internet, 3) receiving support from hospital meetings,
4) receiving support from family, 5) attending lupus sup-
port groups and 6) religious practice [24,26,27] (Figure 1).The conceptual model also includes concepts such as
treatment satisfaction, adherence and the impact of flares
in a ‘future considerations’ box. There was a lack of evi-
dence pertaining to these concepts in the currently avail-
able literature.
The conceptual model also demonstrates the economic
burden of disease, in particular the high medical costs
associated with SLE compared to other chronic diseases
[42]. Substantial levels of inpatient care, medication/pre-
scriptions and visits to healthcare professionals (HCP),
which are all increased by ‘flares’, are the main drivers of
direct costs in the treatment of SLE [43]. The conceptual
model also shows that SLE is associated with high indirect
costs due to lost productivity [5] resulting from un-
employment and absenteeism, [44], with ‘in-flare’ patients
with SLE having increased frequency and duration of time
off work [45,46].
A comparison between this conceptual model and the
model developed by Gallop et al. [22] suggests similar-
ities, although our model provides a broader perspective
on the impact of SLE. There is alignment between the
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hair loss. Impact on work/employment, impact on daily
life/daily activities, lack of independence and emotional
wellbeing are also presented in both models. In terms of
differences, Gallop’s model [22] viewed impacts on social,
family and leisure activities as one concept; however, the
present literature review and model identified these as
separate concepts. The emotional impact is conceptua-
lised as depression or frustration in Gallop’s model [22],
whilst a broader range of emotions associated with SLE
(including worry, anger, embarrassment and shame in
addition to depression and frustration) were identified in
the literature. Unlike the model presented in this paper,
impacts on physical functioning, relationships, sleep,
worry about the ability to conceive/have children, the im-
pact of others’ perceptions and the personal and broader
economic burden are not shown in Gallop’s model. Whilst
fatigue is noted as a symptom in both models, the model
presented in this paper also conceptualises fatigue as an
impact of SLE. Gallop et al. [22] include appearance and
cognition concepts as impacts of SLE but these are cap-
tured as symptoms in the present model. Gallop et al. [22]
also recognise the different triggers that may lead to the
onset or worsening of symptoms in their conceptual
model; however these issues were not identified in the
present literature review.
Review of patient-reported outcomes measures
A total of 23 PRO measures were identified from the arti-
cles reviewed. Of those, 15 measures targeted key concepts
in the conceptual model and were therefore selected for
in-depth review (Table 1). SLE-specific and generic PROs
were categorised according to the concepts measured.
Content validity – conceptual coverage
An overview of the conceptual coverage of each PRO
measure was performed to evaluate content validity
(Table 2). Of all 15 PROs reviewed, only the disease-
specific LupusQoL, LupusPRO, L-QoL and SLEQOL have
documented evidence for involvement of patients with
SLE in concept elicitation and development of items
[50,52,54,55].
In terms of the SLE-specific and generic HRQoL in-
struments, the SF-36v2, LupusQoL and SLEQOL demon-
strated a greater level of conceptual coverage, in terms
of the variety and number of relevant SLE concepts
measured, compared to the other four HRQoL instru-
ments (Table 2).
All three fatigue PROs demonstrated similar levels of
conceptual coverage for SLE, with each measuring fa-
tigue and its impact on daily activities and social func-
tioning (Table 2). The MAF was the only fatigue-related
PRO to measure the impact of fatigue on relationships
(i.e. sexual activity or socialising with friends) and abilityto work. Of the two pain-related PROs, the BPI-SF had
superior conceptual coverage compared to the MPQ,
measuring both pain symptoms and the impact of pain
on a range of aspects of daily life.
As expected, both depression-related PROs were fo-
cussed on the emotional/psychological well-being impact,
but the BDI also measures fatigue (‘tiredness’), patients’ at-
titudes towards their appearance and impact on sleep and
ability to work – concepts which are also relevant to SLE
patients (Table 2). The WPAI:Lupus measures relevant
SLE concepts such as ability to work, disability associated
with lupus and the impact of lupus on activities of daily
living such as housework and childcare.
Face validity
Of all the PRO measures reviewed, only the LupusQoL,
LupusPRO and L-QoL had documented evidence of quali-
tative involvement of patients with SLE to evaluate the
face and content validity through cognitive debriefing
techniques (Table 3). The LupusPRO was pilot tested with
SLE patients, though the face validity was not qualitatively
assessed. Patient insights were used in the development of
the SLEQOL, although only by means of ranking items in
order of importance; the face validity was not qualitatively
assessed. A face validity review suggested that the instruc-
tions and item wording, recall period and response op-
tions for six PRO measures (L-QoL, SF-36v2, EQ-5D-3L,
EQ-5D-5L, FACIT-Fatigue, HADS) appeared acceptable
and appropriate for a SLE population and are in line with
guidance for the use of PROs in clinical trials [11]
(Table 3). The standard version of the SF-36v2 has a four
week recall period, which is unlikely to be acceptable to
regulators. However, the acute version, with a seven day
recall period, is likely to be more acceptable. The item and
instruction wording of each PRO measure was clear, free
of clinical terminology and generally written in simple
language. The response options of these six PROs are
generally clear and appropriate for patients with SLE.
Furthermore, the recall periods were appropriate for
intended use of the measures with patients with SLE.
In contrast, the other nine PROs included features
which may hinder understanding and completion of the
items by patients (Table 3). Four PROs used vague and
insufficiently defined (e.g. ‘leisure and recreational activ-
ities’ and ‘fatigue’ in the MAF) or complex terminology
(e.g. ‘lacerating’ and “spatial” in the MPQ) in the items
and instructions. The individual instructions provided for
the WPAI:Lupus items increase the word count/length,
which may be overwhelming for some patients.
The format of the response options for some PROs
was inconsistent, which may cause confusion to patients
(SLEQOL, MFI, MAF); some used complex terms such
as ‘excruciating’ (MPQ) or were lengthy and ambiguous
(BDI) (Table 3).
Table 1 Patient-reported outcome measures reviewed
Instrument Number
of items
Recall period Response format Reference or rationale for inclusion




28 Last 3 months First 27 items have 4-point scale, ranging
from ‘none’ to ‘severe’. Last item has a
1–10 numerical rating scale (NRS)
[47-49]
LupusQoL [50] 34 Last 4 weeks 5-point scale ranging from ‘never’ to
‘all of the time’
[30,51]
LupusPRO [52] 43 Last 4 weeks 5-point scale ranging from ‘never’ to
‘all of the time’
[52,53]
L-QoL [40] 25 At the moment Dichotomous ‘true’/’not true’ scale [30,40,54]
SLEQOL [55] 40 Last week All 7 point Likert scales, although scales
have different labels (i.e. ‘not difficult at
all’ to ‘very difficult’; ‘not at all’ to
‘extremely troubled’; ‘not at all’ to
‘extremely often’)
[30,54]
Short Form 36 version 2
(SF-36v2) [56]
36 Standard 4-week recall
or Acute 1-week recall
version.
Varies dependent on scale [Yes/No and
3, 5 and 6-point Likert scales].
[30,47,49,54,57-63]
Euroqol 5 Domain (EQ-5D)
(3-Level and 5-Level) [64,65]
6 Recall of ‘today’ for
both 3L and 5
L version.
3-point scale on 3L and 5-point scale
on 5 L version, ranging from absence
to inability to perform activity or
extreme severity of symptom
Previously used in patients with SLE,
and normative data exist for






13 Past 7 days 5-point scale ranging from ‘not at




20 Lately 5-level agreement scale from ‘Yes, that
is true’ to ‘No, that is not true’.
[35]
Multidimensional Assessment
of Fatigue (MAF) [68]
16 Past week 1-10 numerical rating scale (‘not at
all’ – ‘a great deal) for items 1–14.





20 Present pain Mixed, ranging from 2-point to 6-point
scales
[70]
Brief Pain Inventory – Short
Form (BPI-SF) [71]
15 Last 24 hours Most items have an 11 point numerical
rating scale, ranging from 0 = no pain
and 10 = pain. One item has a binary
yes/no response and another ask
patients to shade a diagram to show
where they have pain. One item has a
0%-100% scale increasing in 10%
increments.
Pain is a key symptom of SLE and the




21 Not specified 4-point scale with detailed wording
provided for each response.
Depression is a key concept in SLE. The
BDI has been used previously with





14 Past week 4-point scale Depression is a key concept in SLE. The
HADS has been used previously with






6 Past 7 days Yes/No & NRS Absenteeism and presenteeism is a
major burden for patients with SLE. The
WPAI:Lupus has been used previously
in patients with SLE and normative
data exist for comparison.
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The LupusQoL, EQ-5D and the FACIT-Fatigue demon-
strated the strongest psychometric properties in an SLEpopulation [47,50,75-77] (Table 4). Psychometric valid-
ation of the SLAQ, LupusPRO and SF-36v2 has also been
conducted in SLE [47,52,76,78,79]. None of the other
Table 2 Content validity of patient-reported outcome measure~
Concept identified in
literature review
SLE-specific HRQoL Generic HRQoL Fatigue Pain Depression Work




Marks on skin ✓
Weight gain/bloating ✓ ✓




✓ ✓ ✓ ✓ ✓
Fatigue ✓ ✓ ✓ ✓ ✓ ✓ ✓* ✓* ✓* ✓
Pain ✓ ✓ ✓ ✓ ✓ ✓ ✓
Fever ✓
Weakness ✓ ✓* ✓*
Flu-like symptoms
Impacts
Physical functioning ✓ ✓ ✓ ✓ ✓ ✓* ✓* ✓*
Daily activities ✓ ✓ ✓ ✓ ✓ ✓ ✓* ✓* ✓* ✓* ✓
Sleep problems ✓ ✓ ✓* ✓* (p) ✓*
Emotional/
Psychological
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓* ✓* (p) ✓* ✓ ✓
Social functioning ✓ ✓ ✓ ✓ ✓* ✓* (p) ✓*
Leisure activities ✓ ✓ ✓ ✓* ✓*
Relationships ✓ ✓ ✓ ✓ (p) ✓*
Work & economic
impacts
Work disability ✓ ✓ ✓ ✓* ✓* ✓
Economic impact ✓ ✓ ✓
Total 8/27 11/27 9/27 5/27 10/27 12/27 4/27 6/27 8/27 8/27 1/27 7/27 2/27 1/27 2/27
SLAQ – Systemic Lupus Activity Questionnaire, SF-36v2 – Short Form [36] Health Survey, EQ-5D – EuroQol 5-Dimensions, FACIT-Fatigue - Functional Assessment of Chronic Illness Therapy, MFI – Multidimensional
Fatigue Inventory, MAF – Multidimensional Assessment of Fatigue, MGQ – McGill Pain Scale, BPI – Brief Pain Inventory, BDI – Beck Depression Inventory, HADS – Hospital Anxiety and Depression Scale,
WPAI:Lupus – Work Productivity and Activity Impairment Questionnaire: Lupus.
~ The following symptoms were identified as important in the literature review, but are not measured by current PROs: flu-like symptoms, dry mouth, skin rash, speech problems, vision sensitivity to bright lights,
sensitivity to hot/cold temperatures, reduced hand grip, haematological abnormalities, sleep related respiratory and movement problems $PRO measure has documented evidence of qualitative research with patients

























Table 3 Content and face validity of each patient-reported outcome measure
PRO Instrument Content and face validity evaluated
with SLE patients using cognitive
debriefing methodology





SLAQ ✗ ✓ ✗ ✓
LupusQoL ✓ ✓ ✗ ✓
LupusPRO ✓ ✓ ✗ ✓
L-QoL ✓ ✓ ✓ ✓
SLEQOL ✗ ✗ ‘Fatigue’ not defined ✓ ✗ Confusing
Generic HRQoL
SF-36v2 ✗ ✓ ✗ ✓
EQ-5D# ✗ ✓ ✓ ✓
Fatigue
FACIT-Fatigue ✗ ✓ ✓ ✓
MFI ✗ ✓ ✗ ‘Lately’ too vague ✗ Confusing
MAF ✗ ✗ ‘Fatigue’ not defined ✓ ✗ Confusing
Pain
MPQ ✗ ✗ Complex terms used ✓ ✗ Complex terms used
BPI-SF ✗ ✓ ✗ Some items don’t specify recall ✓
Depression
BDI ✗ ✗ No question wording ✗ None specified ✗ Lengthily
HADS ✗ ✓ ✓ ✓
Work productivity
WPAI:Lupus ✗ ✗ Some complex terms used ✓ ✓
SLAQ – Systemic Lupus Activity Questionnaire, SF-36v2 – Short Form [36] Health Survey, EQ-5D – EuroQol 5-Dimensions, FACIT-Fatigue - Functional Assessment of
Chronic Illness Therapy, MFI – Multidimensional Fatigue Inventory, MAF – Multidimensional Assessment of Fatigue, MGQ – McGill Pain Scale, BPI – Brief Pain
Inventory, BDI – Beck Depression Inventory, HADS – Hospital Anxiety and Depression Scale, WPAI:Lupus – Work Productivity and Activity Impairment Questionnaire: Lupus.
#Result valid for both the EQ-5D-3L and EQ-5D-5L.
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ment properties in patients with SLE. It is important to
acknowledge that many recent randomised controlled
trials (RCTs) in SLE have not incorporated the use of a
patient global assessment of disease activity, thus making
it difficult to determine minimal important differences
(MIDs) for PRO measures. This may contribute to the
lack of evidence pertaining to MIDs in SLE.
Systemic lupus erythematosus specific health-related quality
of life measures
All five SLE-specific HRQOL measures reviewed in depth
had sufficient evidence of internal consistency (i.e. α > 0.7)
[40,47,50,52,55] (Table 4). The LupusQoL, L-QoL and SLE-
QOL had evidence of strong test–retest reliability (i.e.
ICC > 0.7) [40,50], while the test–retest was shown for
LupusPRO for only 7 out of its 11 domains [52]. The
SLAQ had no evidence of test–retest reliability. Only the
LupusQoL and L-QoL had sufficient evidence of validity
for a SLE population [50]. While the SLAQ demonstrated
construct validity [47], it had no evidence that it is capable
of differentiating known groups, and the LupusPROdemonstrated high floor effects [52]. The LupusQoL and
LupusPRO had no evidence of ability to detect change,
while the SLAQ demonstrate a limited sensitivity to a
change in health status but no evidence of responsiveness
to changes to treatment [47].
Generic health-related quality of life measures
[79] Both of the generic HRQoL measures reviewed had
sufficient evidence of test–retest reliability [75,80,81] and
both demonstrated sufficient evidence of validity [80,81]
(Table 4).
The SF-36v2 has been validated in many different
health conditions and is a widely used and accepted
measure of HRQoL [80,81]. More importantly, in an
SLE population, the SF-36v2 has demonstrated evidence
of internal consistency reliability, concurrent validity and
known groups validity [79]. The EQ-5D showed evidence of
validity and an ability to detect change in patients with SLE
[76] despite being commonly associated with ceiling and
floor effects [82]. Of note, the SF36v2 is able to detect
change in many conditions, including rheumatoid arthritis
[80,81] and more recently, distribution and anchor-based
Table 4 Psychometric properties of patient-reported outcome measures in patients with SLE
Instrument Psychometrically
validated in a SLE
population










SLAQ ✓ [47,78] ✓ (0.87) [47] - ✓ [47,50] - ✓ [78] ✓ [47]
LupusQoL ✓ [50] ✓ (>0.70) [50] ✓ (0.72-0.93) [50] ✓ [50] ✓ [50] ✓ [50] -




✓ [52,76] ✓ [52] -
L-QoL ✓ [40] ✓ (0.92) [40] ✓ (0.92) [40] - ✓ [40] ✓ [40] -
SLEQOL ✓ [55] ✓ (0.95) [55] ✓ (0.83) [55] ✗ (High floor
effects) [55]
- Partial [55] Partial [55]
SF-36v2 ✗ Partial (>0.70) [80,81] Partial [80,81] Partial [80,81] Partial [80,81] Partial [80,81]. ✗ (for SLE) [55,60]
Partial [80]
EQ-5D ✓ [75] - EQ-5D Index: Partial
(0.89) [75] EQ-5D
VAS: Partial (0.77) [75]
✗ [82] ✓ [76] ✓ [76] ✓ [76]
FACIT-Fatigue ✓ [77] ✓ (>0.95) [77] Partial (0.95) [83] - ✓ [77] ✓ [77] ✓ [77]
MFI ✗ Partial (0-68-0.89) [84] - Partial [84,85] I Partial [84,86] Partial [84] Partial [87]
MAF ✗ Partial (0.93) [68] Partial (0.87) [88] Partial [89] Partial [90] Partial [68] Partial [91]
MPQ ✗ Partial (α not provided) [69] Partial (r= > 0.70) [69,92] - - Partial [93] Partial [94]
BPI-SF ✗ Partial (0.80-0.92) [95] Partial (0.83-0.88) [96] Partial [95,97,98] Partial [95,99] Partial [99] Partial [100,101]
BDI ✗ Partial (0.81) [102] Partial (0.93) [102] Partial [102,103] Partial [102,103] Partial [102] -
HADS ✗ Partial (0.83, Anxiety sub-scale;
0.82, Depression sub-scale) [104]
Partial (0.84-0.85 for both
sub-scales) [105]
Partial [73,104] Partial [105] Partial [104,106] Partial [105]
WPAI:Lupus ✗ - Partial (Pearson’s: 0.71-0.75) [74] - Partial [107] Partial [108] Partial [107]
SLAQ – Systemic Lupus Activity Questionnaire, SF-36v2 – Short Form [36] Health Survey, EQ-5D – EuroQol 5-Dimensions, FACIT-Fatigue - Functional Assessment of Chronic Illness Therapy, MFI – Multidimensional
Fatigue Inventory, MAF – Multidimensional Assessment of Fatigue, MGQ – McGill Pain Scale, BPI – Brief Pain Inventory, BDI – Beck Depression Inventory, HADS – Hospital Anxiety and Depression Scale,
WPAI:Lupus – Work Productivity and Activity Impairment Questionnaire: Lupus.


























Holloway et al. Health and Quality of Life Outcomes 2014, 12:116 Page 10 of 14
http://www.hqlo.com/content/12/1/116estimates suggest MIDs of approximately 3–6 points in an
SLE population [79].Fatigue measures
Of the fatigue measures, the FACIT-Fatigue demonstrated
the strongest evidence of internal consistency reliability,
known groups validity, concurrent validity, ability to de-
tect change in a SLE population [77] (Table 4) and test-
retest reliability in psoriatic arthritis [83]. Furthermore,
the FACIT-Fatigue has shown strong evidence of internal
consistency reliability and known groups validity, with an
MID of 3–4 points in rheumatoid arthritis [91]. The MFI
and MAF had sufficient evidence of internal consistency
[68,84], though Cronbach’s α for one of the MFI domains
was below 0.7 [84], and the MAF had evidence of test–
retest reliability (in cancer) [88]. While not validated in a
SLE population, the MFI and MAF had sufficient evidence
of validity and an ability to detect for Sjögren’s syndrome
and rheumatoid arthritis (other autoimmune inflamma-
tory conditions) [68,84,86,89,90] but evidence of the ability
of the MAF to detect change was limited to cancer pa-
tients [87].Pain measures
In terms of the pain items, neither the BPI-SF nor MPQ
have been validated in SLE (Table 4). In other condi-
tions, the BPI-SF demonstrated the strongest evidence of
both internal consistency (α > 0.7) and test-retest reliabil-
ity (ICC > 0.7) [95,96]. The MPQ had sufficient evidence
of test-retest reliability also [69,92] but only provided
partial evidence of internal consistency [69]. The BPI-SF
had acceptable evidence of validity [95,97-99]. In con-
trast, the MPQ had evidence of concurrent validity only
[93]. The MPQ and BPI-SF demonstrated an ability to
detect changes, with both providing evidence of respon-
siveness to treatment in musculoskeletal pain (MPQ)
[94], cancer and rheumatoid arthritis patients (BPI-SF)
[100,101].Depression measures
Neither the BDI nor HADS have been validated in SLE.
However, both measures have evidence of reliability in
other conditions [102,104,105] (Table 4). Both measures
have sufficient evidence of validity in the general popula-
tion and psychiatric patients [73,102-106], though the
construct validity of the BDI varies, with the number of
factors ranging from three to seven depending on the dis-
ease [102]. Of the two depression measures, only the
HADS provides evidence of ability to detect change in re-
sponse to intervention in different diseases, including de-
pression, neurotic disorder, cancer and heart disease [105].Work productivity measure
There is no documented evidence of the psychometric
properties of the WPAI:Lupus in SLE, though item con-
tent in the general health version (WPAI:GH) is highly
consistent with the ‘specific health problem’ version of the
measure (WPAI:SHP) [109]. The content and item word-
ing of the WPAI:GH and the WPAI:SHP is the same, with
the exception of the term ‘general health’ in the WPAI:
GH, which is replaced with the relevant disease. For the
WPAI:Lupus, ‘general health’ is replaced with ‘lupus’.
Therefore, the validity of the WPAI:Lupus can be partially
demonstrated by acceptable concurrent and known
groups validity of the general health version of the
measure (WPAI:GH) in the general population [74] and
in rheumatoid arthritis [108]. The WPAI:GH also had
evidence of test–retest reliability in rheumatoid arthritis
[74] but none of internal consistency. Moreover, the anky-
losing spondylitis-specific WPAI:SpA has shown known
groups validity and responsiveness to treatment of anky-
losing spondylitis [107].
Discussion
To understand the value of therapies for SLE from the
patient-perspective, PRO measures should be included in
clinical trials in conjunction with well-established clinical
assessments. The selection of suitable measures to assess
SLE-related symptoms and impacts in clinical trials re-
quires careful consideration [14,15]. This study therefore
sought to develop a conceptual model of the key symp-
toms and impacts associated with SLE to help support
identification of suitable endpoints for clinical trials in
SLE [14,15]. The model also aimed to integrate the eco-
nomic burden of SLE to patients, health care providers
and the wider society.
The key patient-reported concepts identified within the
model were fatigue, pain, cognition, daily activities, emo-
tional well-being, physical/social functioning and work
productivity. The subjective nature of many SLE symp-
toms and impacts requires accurate and reliable measure-
ment of these symptoms based on patient self-report. In
light of this, our study also sought to review and evaluate
the face and content validity and psychometric properties
of PROs that may be appropriate for use in a SLE popula-
tion. To our knowledge, this is the first comprehensive re-
view of PROs for the whole range of key symptoms and
impacts experienced specifically by patients with SLE. The
American College of Rheumatology conducted a review to
recommend measures for inclusion in SLE trials [34], but
this was limited to the evaluation of fatigue. In a review of
outcome measures in SLE clinical trials, Strand et al. [54]
included a brief summary of the measurement properties
of a small number of selected HRQoL measures used pre-
viously in SLE trials, but this review did not include evalu-
ation of face and content validity.
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http://www.hqlo.com/content/12/1/116The current review showed that the LupusQoL, SLE-
QOL, SF-36v2, FACIT-Fatigue and BPI-SF demonstrated
face and content validity and were psychometrically strong
as measures of the key concepts identified in the concep-
tual model. The FACIT-Fatigue and BPI-SF appeared to
be the strongest instruments. In addition, the generic
SF-36v2 and EQ-5D measures are widely used in trials
with patients with SLE and are recognised and accepted
by clinical, patient, regulatory, reimbursement and aca-
demic communities.
A recent qualitative study involving SLE patients con-
cluded that the FACIT-Fatigue is a relevant measure of
fatigue in SLE [28]. Furthermore, the psychometric prop-
erties of the FACIT-Fatigue in an SLE population are well
documented [77]. In contrast, the American College of
Rheumatology study from 2007 suggest the Fatigue Sever-
ity Scale (FSS) as a measure of fatigue in SLE [34].
However, our review questions the lack of SLE patient in-
volvement in the initial development of the FSS; and the
lack of supporting evidence of its face and content validity.
Furthermore, the psychometric properties of the FSS have
been assessed but in a limited number of patients with
SLE [110,111]. Indeed, of all the PRO measures reviewed,
only three Lupus-specific measures (LupusQoL, Lupu-
sPRO and L-QoL) have documented evidence of qualita-
tive input from patients with SLE.
Important in the measurement of SLE is to acknow-
ledge that patients may experience many symptom-free
days, followed by a severe flare. Flares are likely to im-
pact patients’ health-related quality of life [7,10], as well
as having a wider society and economic impact [45]. For
example, patients with flares incur higher direct and
indirect costs compared with those without flares [45].
Therefore, PRO measurement of the impact of flares may
be considered in future clinical trials in patients with SLE
in addition to clinical outcome assessments [14,15]. Des-
pite this, no PRO measures were identified which target
the impact of flares on humanistic burden. In addition,
SLE often involves day-to-day symptom fluctuations due
to these flares, thus the recall period of the measurement
instrument is also an important consideration. PROs with
shorter recall periods may underestimate symptom bur-
den and may place undue demand on patients; however,
longer recall period may not allow for reliable symptom
and impact reporting.
Whilst the validity of this literature review is strength-
ened by the inclusion of qualitative and quantitative
studies, with the review of PRO measures conducted in
accordance with regulatory guidelines [11,12,23], there
are inherent limitations. Firstly, an assessment of the
quality of the studies identified from the literature search
was not conducted, so as not to limit our search. The re-
view was however intended to be as inclusive and wide-
ranging as possible to capture all of the key concepts forthe development of the conceptual model and to ensure
that atypical symptoms were not missed. Secondly, after
key SLE symptoms and impacts in the conceptual model
were identified, PROs were selected for in-depth review
on the basis of measurement of those fundamental symp-
toms and impacts. PRO measures of other symptoms of
SLE not reported in the conceptual model were thus de-
prioritised and therefore not included in the in-depth re-
view. Nevertheless, PRO measures for some key concepts
identified in the model (for example, skin manifestations
of the disease, impact of flares and treatment satisfaction)
were either not identified from the literature search, or no
PRO has been used to measure these concepts in SLE.
This represents a gap in knowledge which may benefit
from further research.
PROs are acknowledged as complementary to more ob-
jective measures and are being incorporated more fre-
quently into clinical trials and clinical practice [112]. The
recognition and measurement of disease experience from
the patient’s perspective is an important factor for SLE
clinical trial design and health care decision makers. The
results of the present study, demonstrating the suitability
of PROs for use in clinical trials of SLE within the guid-
ance provided by the FDA and EMA [11,12,14,15], can
hopefully be of benefit to clinical research within SLE.
Conclusion
SLE is a condition associated with high unmet need and
considerable burden to patients, as demonstrated by the
conceptual model presented in this paper. This review
highlights the existing patient-reported measures of
HRQoL, SLE signs and symptoms and work productiv-
ity that demonstrate appropriate content and face valid-
ity and are psychometrically adequate for a population
of patients with SLE, and as a result such measures may
be suitable for use in SLE clinical trials.
Abbreviations
BDI: Beck depression inventory; BPI-SF: Brief Pain Inventory – Short Form;
EMA: European Medicines Agency; FDA: Food and Drug Administration;
HRQoL: Health-related quality of life; IQWIG: Germany, Institute for Quality
and Efficiency in Healthcare; LN: Lupus Nephritis; MPQ: McGill Pain
Questionnaire; MAF: Multidimensional Assessment of Fatigue; NICE: UK,
National Institute of Health and Clinical Excellence; PROs: Patient-reported
Outcomes; SLE: Systemic lupus erythematosus; FACIT-Fatigue: The Functional
Assessment of Chronic Illness Therapy - Fatigue Scale; HADS: The Hospital
Anxiety and Depression Scale; WPAI:Lupus: Work Productivity and Activity
Impairment Questionnaire: Lupus.
Competing interests
The study was funded by Novo Nordisk A/S, Denmark and conducted by
Adelphi Values. LHo, LHu, LHe, CP and HK are employees of Adelphi Values
(or were employees at the time the research was conducted). LHø, MS-L,
and BBH are employees of Novo Nordisk A/S.
Authors’ contributions
LHo, LHu, LHe, CP and HK participated in the study conception and design,
analysis and interpretation of literature, development of the conceptual
model, and reviewed and approved the manuscript. LHø, MS-L, and BBH
participated in the study conception and design, analysis and interpretation,
Holloway et al. Health and Quality of Life Outcomes 2014, 12:116 Page 12 of 14
http://www.hqlo.com/content/12/1/116reviewed and approved the final version of the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
Ben Rousseau, Steven Blackburn, and Mark Forshaw, all of Adelphi Values,
provided medical writing support for this article.
Author details
1Adelphi Values, Adelphi Mill, Bollington, Macclesfield, Cheshire SK10 5JB, UK.
2Abacus International, Manchester One, Manchester M1 3LD, UK. 3The
University of Manchester, Oxford Road, Manchester M13 9PL, UK. 4Novo
Nordisk A/S, Novo Allé 1, 2880 Bagsvaerd, Denmark.
Received: 10 March 2014 Accepted: 8 July 2014
Published: 22 July 2014
References
1. Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N: Systematic
review of the epidemiology of systemic lupus erythematosus in the
Asia-Pacific region: prevalence, incidence, clinical features, and mortality.
Arthritis Care Res 2012, 64:159–168.
2. Danchenko N, Satia JA, Anthony MS: Epidemiology of systemic lupus
erythematosus: a comparison of worldwide disease burden. Lupus 2006,
15:308–318.
3. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM: Prevalence of adult
systemic lupus erythematosus in California and Pennsylvania in 2000:
estimates obtained using hospitalization data. Arthritis Rheum 2007,
56:2092–2094.
4. Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME: The
geoepidemiology of systemic lupus erythematosus [abstract]. Autoimmun
Rev 2010, 9:A277–A287.
5. Zhu TY, Tam LS, Li EK: Cost-of-illness studies in systemic lupus
erythematosus: a systematic review. Arthritis Care Res (Hoboken) 2011,
63:751–760.
6. Manson JJ, Rahman A: Systemic lupus erythematosus. Orphanet J Rare Dis
2006, 1:6.
7. Ruperto N, Hanrahan LM, Alarcon GS, Belmont HM, Brey RL, Brunetta P,
Buyon JP, Costner MI, Cronin ME, Dooley MA, Filocamo G, Fiorentino D,
Fortin PR, Franks AG Jr, Gilkeson G, Ginzler E, Gordon C, Grossman J,
Hahn B, Isenberg DA, Kalunian KC, Petri M, Sammaritano L,
Sánchez-Guerrero J, Sontheimer RD, Strand V, Urowitz M, von Feldt JM,
Werth VP, Merrill JT: International consensus for a definition of disease
flare in lupus. Lupus 2011, 20:453–462.
8. Lahita RG: Systemic Lupus Erythematosus. London: Elsevier; 2004.
9. Lupus: Statistics on Lupus. Foundation of America. [http://www.lupus.org/
about/statistics-on-lupus]
10. Jolly M, Pickard AS, Wilke C, Mikolaitis RA, Teh LS, McElhone K, Fogg L,
Block J: Lupus-specific health outcome measure for US patients: the
LupusQoL-US version. Ann Rheum Dis 2010, 69:29–33.
11. Food & Drug Administration: Guidance For Industry: Patient-Reported
Outcome Measures: Use In Medical Product Development To Support
Labelling Claims; 2009. http://www.fda.gov/downloads/Drugs/Guidances/
UCM193282.pdf.
12. European Medicines Agency: Reflection Paper on the Regulatory Guidance for
the use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of
Medicinal Products; 2005. http://www.ispor.org/workpaper/emea-hrql-
guidance.pdf.
13. Department of Health: Equity and Excellence: Liberating the NHS; 2010.
https://www.gov.uk/government/uploads/system/uploads/attachment_
data/file/213823/dh_117794.pdf.
14. Food & Drug Administration: Guidance for Industry: Systemic Lupus
Erythematosus - Developing Medical Products for Treatment; 2010.
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory
Information/Guidances/ucm072063.pdf.
15. European Medicines Agency: Guideline on Clinical Investigation of Medicinal
Products for the Treatment of Systemic Lupus Erythematosus, Cutaneous Lupus
and Lupus Nephritis (Draft); 2013. http://www.ema.europa.eu/docs/en_GB/
document_library/Scientific_guideline/2013/03/WC500139615.pdf.
16. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P: Outcome
measures to be used in clinical trials in systemic lupus erythematosus.
J Rheumatol 1999, 26:490–497.17. Smolen JS, Strand V, Cardiel M, Edworthy S, Furst D, Gladman D, Gordon C,
Isenberg DA, Klippel JH, Petri M, Simon L, Tugwell P, Wolfe F: Randomized
clinical trials and longitudinal observational studies in systemic lupus
erythematosus: consensus on a preliminary core set of outcome
domains. J Rheumatol 1999, 26:504–507.
18. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement [abstract].
BMJ 2009, 339:b2535.
19. Systematic Reviews: CRD’s guidance for undertaking systematic reviews
in health care. http://www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf.
20. Earp JA, Ennett ST: Conceptual models for health education research and
practice. Health Educ Res 1991, 6:163–171.
21. Rothman ML, Beltran P, Cappelleri JC, Lipscomb J, Teschendorf B, the
Mayo/F. D. A. Patient-Reported Outcomes Consensus Meeting Group:
Patient-reported outcomes: conceptual issues. Value Health 2007, 10:S66–S75.
22. Gallop K, Nixon A, Swinburn P, Sterling KL, Naegeli AN, Silk ME:
Development of a conceptual model of health-related quality of life for
systemic lupus erythematosus (SLE) from the patients’ perspective.
Lupus 2012, 21:934–943.
23. Mokkink L, Terwee C, Patrick D, Alonso J, Stratford P, Knol D, Bouter L, Vet H:
The COSMIN checklist for assessing the methodological quality of
studies on measurement properties of health status measurement
instruments: an international Delphi study. Qual Life Res 2010, 19:539–549.
24. Beckerman NL: Living with lupus: a qualitative report. Soc Work Health
Care 2011, 50:330–343.
25. McElhone K, Abbott J, Gray J, Williams A, Teh LS: Patient perspective of
systemic lupus erythematosus in relation to health-related quality of life
concepts: a qualitative study. Lupus 2010, 19:1640–1647.
26. Robinson J, Aguilar D, Schoenwetter M, Dubois R, Russak S,
Ramsey-Goldman R, Navarra S, Hsu B, Revicki D, Cella D, Rapaport MH,
Renahan K, Ress R, Wallace D, Weisman M: Impact of systemic lupus
erythematosus on health, family, and work: the patient perspective.
Arthritis Care Res 2010, 62:266–273.
27. Mattsson M, Moller B, Stamm T, Gard G, Bostrom C: Uncertainty and
opportunities in patients with established systemic Lupus
Erythematosus: a qualitative study. Musculoskeletal Care 2012, 10:1–12.
28. Kosinski M, Gajria K, Fernandes AW, Cella D: Qualitative validation of the
FACIT-fatigue scale in systemic lupus erythematosus. Lupus 2013, 22:422–430.
29. Schneider M, Schmeding A, Carnarius H, Ager M, McWade V: Systemic lupus
erythematosus (SLE): understanding the burden. Value Health 2010, 13:A470.
30. Yee CS, McElhone K, Teh LS, Gordon C: Assessment of disease activity and
quality of life in systemic lupus erythematosus - New aspects. Best Pract
Res Clin Rheumatol 2009, 23:457–467.
31. Aberer E: Epidemiologic, socioeconomic and psychosocial aspects in
lupus erythematosus. Lupus 2010, 19:1118–1124.
32. Strand V, Galateanu C, Pushparajah DS, Nikai E, Sayers J, Wood R, van
Vollenhoven RF: Limitations of current treatments for systemic lupus
erythematosus: a patient and physician survey. Lupus 2013, 22:819–826.
33. Pettersson S, Lovgren M, Eriksson LE, Moberg C, Svenungsson E,
Gunnarsson I, Henriksson EW: An exploration of patient-reported
symptoms in systemic lupus erythematosus and the relationship to
health-related quality of life. Scand J Rheumatol 2012, 41:383–390.
34. Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for
Fatigue: Measurement of fatigue in systemic lupus erythematosus: a
systematic review. Arthritis Care Res 2007, 57:1348–1357.
35. Cleanthous S, Tyagi M, Isenberg DA, Newman SP: What do we know about
self-reported fatigue in systemic lupus erythematosus? Lupus 2012,
21:465–476.
36. Ramsey-Goldman R, Rothrock N: Fatigue in systemic lupus erythematosus
and rheumatoid arthritis. PM&R 2010, 2:384–392.
37. Danoff-Burg S, Friedberg F: Unmet needs of patients with systemic lupus
erythematosus. Behav Med 2009, 35:5–13.
38. Yazdany J, Yelin E: Health-related quality of life and employment among
persons with systemic Lupus Erythematosus. Rheum Dis Clin North Am
2010, 36:15–32.
39. Robinson M, Sheets CS, Currie LM: Systemic lupus erythematosus: a
genetic review for advanced practice nurses. J Am Acad Nurse Pract 2011,
23:629–637.
40. Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P,
Veale DJ: The development of the L-QoL: a quality-of-life instrument specific
to systemic lupus erythematosus. Ann Rheum Dis 2009, 68:196–200.
Holloway et al. Health and Quality of Life Outcomes 2014, 12:116 Page 13 of 14
http://www.hqlo.com/content/12/1/11641. Johnsson PM, Sandqvist G, Bengtsson A, Nived O: Hand function and
performance of daily activities in systemic lupus erythematosus. Arthritis
Rheum 2008, 59:1432–1438.
42. Carls G, Li T, Panopalis P, Wang S, Mell AG, Gibson TB, Goetzel RZ: Direct
and indirect costs to employers of patients with systemic lupus
erythematosus with and without nephritis. J Occup Environ Med 2009,
51:66–79.
43. Zhu TY, Tam LS, Li EK: The socioeconomic burden of systemic lupus
erythematosus: state-of-the-art and prospects. Expert Rev Pharmacoecon
Outcomes Res 2012, 12:53–69.
44. Yelin E, Katz P: Introduction to special section: cost and social and
psychological impact of rheumatic diseases. Arthritis Rheum 2008, 59:457.
45. Zhu TY, Tam LS, Lee VWY, Lee KKC, Li EK: The impact of flare on disease
costs of patients with systemic lupus erythematosus. Arthritis Rheum
2009, 61:1159–1167.
46. Aghdassi E, Zhang W, St. Pierre Y, Clarke AE, Morrison S, Peeva V,
Landolt-Marticorena C, Su J, Reich H, Scholey J, Herzenberg A, Pope JE,
Peschken C, Lunnet Canios I, Wither JE, Fortin PR: Healthcare cost and loss
of productivity in a Canadian population of patients with and without
lupus nephritis. J Rheumatol 2011, 38:658–666.
47. Yazdany J, Yelin EH, Panopalis P, Trupin L, Julian L, Katz PP: Validation of
the systemic lupus erythematosus activity questionnaire in a large
observational cohort. Arthritis Rheum 2008, 59:136–143.
48. Askanase AD, Castrejon I, Pincus T: Quantitative data for care of patients
with systemic lupus erythematosus in usual clinical settings: a patient
multidimensional health assessment questionnaire and physician
estimate of noninflammatory symptoms. J Rheumatol 2011, 38:1309–1316.
49. Moldovan I, Katsaros E, Carr FN, Cooray D, Torralba K, Shinada S, Ishimori ML,
Jolly M, Wallace DJ, Weisman MH, Nicassio PM: The Patient Reported
Outcomes in Lupus (PATROL) study: role of depression in health-related
quality of life in a Southern California lupus cohort. Lupus 2011, 20:1285–1292.
50. McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, Peers K,
Isenberg D, Ferenkeh-Koroma A, Griffiths B, Akil M, Maddison P, Teh LS:
Development and validation of a disease-specific health-related quality
of life measure, the LupusQoL, for adults with systemic lupus
erythematosus. Arthritis Rheum 2007, 57:972–979.
51. Strand V, Chu AD: Generic versus disease-specific measures of
health-related quality of life in systemic lupus erythematosus.
J Rheumatol 2011, 38:1821–1823.
52. Jolly M, Pickard AS, Block JA, Kumar RB, Mikolaitis RA, Wilke CT, Rodby RA, Fogg
L, Sequeira W, Utset TO, Cash TF, Moldovan I, Katsaros E, Nicassio P, Ishimori
ML, Kosinsky M, Merrill JT, Weisman MH, Wallace DJ: Disease-specific patient
reported Outcome tools for systemic lupus erythematosus. Semin Arthritis
Rheum 2012, 42:56–65.
53. Jolly M, Garris CP, Jhingran PM, Mikolaitis RA, Dennis G, Wallace DJ, Clarke A,
Dooley MA, Parke A, Strand V, Alárcon GS, Kosinski M: Development of the
lupus impact tracker: a tool for patients and physicians to assess and
monitor the impact of systemic lupus erythematosus (SLE). Arthritis Care
Res (Hoboken) 2011, 14:A65–A66.
54. Strand V, Chu AD: Measuring outcomes in systemic lupus erythematosus
clinical trials. Expert Rev Pharmacoecon Outcomes Res 2011, 11:455–468.
55. Leong KP, Kong KO, Thong BYH, Koh ET, Lian TY, Teh CL, Cheng YK,
Chng HH, Badsha H, Law WG, Lau TC, Chew LC, Ho HJ, Pong LY, Hoi LS,
Sangeetha N, Chan SP, Howe HS: Development and preliminary validation
of a systemic lupus erythematosus-specific quality-of-life instrument
(SLEQOL). Rheumatology 2005, 44:1267–1276.
56. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey
(SF-36). I. Conceptual framework and item selection. Med Care 1992,
30:473–483.
57. Almehed K, Carlsten H, Forsblad-D’Elia H: Health-related quality of life in
systemic lupus erythematosus and its association with disease and work
disability. Scand J Rheumatol 2010, 39:58–62.
58. Benitha R, Tikly M: Functional disability and health-related quality of life
in South Africans with rheumatoid arthritis and systemic lupus
erythematosus. Clin Rheumatol 2007, 26:24–29.
59. Kulczycka L, Sysa-Jedrzejowska A, Robak E: Quality of life and satisfaction
with life in SLE patients-the importance of clinical manifestations.
Clin Rheumatol 2010, 29:991–997.
60. Kuriya B, Gladman DD, Ibañez D, Urowitz MB: Quality of life over time in
patients with systemic lupus erythematosus. Arthritis Care Res 2008,
59:181–185.61. Mok CC, Ho LY, Cheung MY, Yu KL, To CH: Effect of disease activity and
damage on quality of life in patients with systemic lupus erythematosus:
a 2-year prospective study. Scand J Rheumatol 2009, 38:121–127.
62. Sliem H, Tawfik G, Khalil KA, Ibrahim N: Pattern of systemic lupus
erythematosus in Egyptian patients: the impact of disease activity on
the quality of life. Pan Afr Med J 2010, 6:14.
63. Zhu TY, Tam LS, Lee VWY, Lee KK, Li EK: Relationship between flare
and health-related quality of life in patients with systemic lupus
erythematosus. J Rheumatol 2010, 37:568–573.
64. The EuroQol Group: EuroQol-a new facility for the measurement of
health-related quality of life. Health Policy 1990, 16:199–208.
65. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G,
Badia X: Development and preliminary testing of the new five-level
version of EQ-5D (EQ-5D-5L). Qual Life Res 2011, 20:1727–1736.
66. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E: Measuring fatigue
and other anemia-related symptoms with the Functional Assessment of
Cancer Therapy (FACT) measurement system. J Pain Symptom Manage
1997, 13:63–74.
67. Smets EM, Garssen B, Bonke B, De Haes JC: The Multidimensional Fatigue
Inventory (MFI) psychometric qualities of an instrument to assess
fatigue. J Psychosom Res 1995, 39:315–325.
68. Belza BL, Henke CJ, Yelin EH, Epstein WV, Gilliss CL: Correlates of fatigue in
older adults with rheumatoid arthritis. Nurs Res 1993, 42:93–99.
69. Melzack R: The McGill Pain Questionnaire: major properties and scoring
methods. Pain 1975, 1:277–299.
70. Ozel F, Argon G: The effects of fatigue and pain on daily life activities in
systemic lupus erythematosus. 2011Abstracts from 10th Congress of the
European Federation of Internal Medicine [abstract. Eur J Intern Med 2011,
22:S70.
71. Cleeland CS, Ryan KM: Pain assessment: global use of the Brief Pain
Inventory. Ann Acad Med Singapore 1994, 23:129–138.
72. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for
measuring depression. Arch Gen Psychiatry 1961, 4:561–571.
73. Zigmond AS, Snaith RP: The hospital anxiety and depression scale.
Acta Psychiatr Scand 1983, 67:361–370.
74. Reilly MC, Zbrozek AS, Dukes EM: The validity and reproducibility of a
work productivity and activity impairment instrument.
Pharmacoeconomics 1993, 4:353–365.
75. Konig HH, Ulshofer A, Gregor M, von Tirpitz C, Reinshagen M, Adler G,
Leidl R: Validation of the EuroQol questionnaire in patients with
inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002, 14:1205–1215.
76. Aggarwal R, Wilke CT, Pickard AS, Vats V, Mikolaitis R, Fogg L, Block JA, Jolly M:
Psychometric properties of the EuroQol-5D and short form-6D in patients
with systemic lupus erythematosus. J Rheumatol 2009, 36:1209–1216.
77. Lai JS, Beaumont JL, Ogale S, Brunetta P, Cella D: Validation of the
functional assessment of chronic illness therapy-fatigue scale in patients
with moderately to severely active systemic lupus erythematosus,
participating in a clinical trial. J Rheumatol 2011, 38:672–679.
78. Karlson EW, Daltroy LH, Rivest C, Ramsey-Goldman R, Wright EA,
Partridge AJ, Liang MH, Fortin PR: Validation of a Systemic Lupus Activity
Questionnaire (SLAQ) for population studies. Lupus 2003, 12:280–286.
79. Beaumont JLL J, Cella D, Brunetta P, Ogale S: Validation of the SF-36 in
Patients with Systemic Lupus Erythematosus (SLE). Arthritis Rheum 2009,
60:296.
80. Busija L, Pausenberger E, Haines TP, Haymes S, Buchbinder R, Osborne RH:
Adult measures of general health and health-related quality of life:
Medical Outcomes Study Short Form 36-Item (SF-36) and Short Form
12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP),
Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D
(SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale
(QWB), and Assessment of Quality of Life (AQOL) [abstract]. Arthritis Care
Res 2011, 63:S383–S412.
81. QualityMetric Inc.: User’s Manual for the SF-36v2 Health Survey. 3rd edition;
2011. http://www.qualitymetric.com/WhatWeDo/ManualsUserGuides/
UsersManualfortheSF36v2HealthSurvey/tabid/328/Default.aspx.
82. Gignac MAM, Cao X, McAlpine J, Badley EM: Measures of disability:
Arthritis Impact Measurement Scales 2 (AIMS2), Arthritis Impact
Measurement Scales 2-Short Form (AIMS2-SF), The Organization for
Economic Cooperation and Development (OECD) Long-Term Disability
(LTD) Questionnaire, EQ-5D, World Health Organization Disability
Assessment Schedule II (WHODASII), Late-Life Function and Disability
Holloway et al. Health and Quality of Life Outcomes 2014, 12:116 Page 14 of 14
http://www.hqlo.com/content/12/1/116Instrument (LLFDI), and Late-Life Function and Disability
Instrument-Abbreviated Version (LLFDI-Abbreviated) [abstract]. Arthritis
Care Res 2011, 63:S308–S324.
83. Chandran V, Bhella S, Schentag C, Gladman DD: Functional assessment of
chronic illness therapy-fatigue scale is valid in patients with psoriatic
arthritis. Ann Rheum Dis 2007, 66:936–939.
84. Goodchild CE, Treharne GJ, Booth DA, Kitas GD, Bowman SJ: Measuring
fatigue among women with Sjogren’s syndrome or rheumatoid arthritis:
a comparison of the Profile of Fatigue (ProF) and the Multidimensional
Fatigue Inventory (MFI). Musculoskeletal Care 2008, 6:31–48.
85. Lin J-M, Brimmer D, Maloney E, Nyarko E, BeLue R, Reeves W: Further
validation of the Multidimensional Fatigue Inventory in a US adult
population sample. Popul Health Metrics 2009, 7:18.
86. Barendregt PJ, Visser MR, Smets EM, Tulen JH, van den Meiracker AH,
Boomsma F, Markusse HM: Fatigue in primary Sjogren’s syndrome.
Ann Rheum Dis 1998, 57:291–295.
87. Smets E, Garssen B, Cull A, De Haes J: Application of the multidimensional
fatigue inventory (MFI-20) in cancer patients receiving radiotherapy. Br J
Cancer 1996, 73:241.
88. Meek PM, Nail LM, Barsevick A, Schwartz AL, Stephen S, Whitmer K, Beck SL,
Jones LS, Walker BL: Psychometric Testing of Fatigue Instruments for Use
With Cancer Patients. Nurs Res 2000, 49:181–190.
89. Wolfe F: Fatigue assessments in rheumatoid arthritis: comparative
performance of visual analog scales and longer fatigue questionnaires in
7760 patients. Arthritis Rheumatol 2004, 31:1896–1902.
90. Jump RL, Fifield J, Tennen H, Reisine S, Giuliano AJ: History of affective
disorder and the experience of fatigue in rheumatoid arthritis. Arthritis
Care Res 2004, 51:239–245.
91. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J: Validation
of the Functional Assessment of Chronic Illness Therapy Fatigue Scale
relative to other instrumentation in patients with rheumatoid arthritis.
J Rheumatol 2005, 32:811–819.
92. Roche PA, Klestov AC, Heim HM: Description of stable pain in rheumatoid
arthritis: a 6 year study. Arthritis Rheumatol 2003, 30:1733–1738.
93. Creamer P, Lethbridge-Cejku M, Hochberg M: Determinants of pain
severity in knee osteoarthritis: effect of demographic and psychosocial
variables using 3 pain measures. Arthritis Rheumatol 1999, 26:1785.
94. Jenkinson C, Carroll D, Egerton M, Frankland T, McQuay H, Nagle C:
Comparison of the sensitivity to change of long and short form pain
measures. Qual Life Res 1995, 4:353–357.
95. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA,
Pandya KJ: Pain and its treatment in outpatients with metastatic cancer.
N Engl J Med 1994, 330:592–596.
96. Mendoza T, Mayne T, Rublee D, Cleeland C: Reliability and validity of a
modified Brief Pain Inventory short form in patients with osteoarthritis.
Eur J Pain 2006, 10:353–361.
97. Atkinson TM, Rosenfeld BD, Sit L, Mendoza TR, Fruscione M, Lavene D,
Shaw M, Li Y, Hay J, Cleeland CS, Scher HI, Breitbart WS, Basch E: Using
confirmatory factor analysis to evaluate construct validity of the Brief
Pain Inventory (BPI). J Pain Symptom Manage 2011, 41:558–565.
98. Williams VSL, Smith MY, Fehnel SE: The validity and utility of the BPI
interference measures for evaluating the impact of osteoarthritic pain.
J Pain Symptom Manag 2006, 31:48–57.
99. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS: Validity of
the brief pain inventory for use in documenting the outcomes of
patients with noncancer pain. Clin J Pain 2004, 20:309–318.
100. Daut RL, Cleeland CS, Flannery RC: Development of the Wisconsin Brief
Pain Questionnaire to assess pain in cancer and other diseases. Pain
1983, 17:197–210.
101. Mease PJ, Spaeth M, Clauw DJ, Arnold LM, Bradley LA, Russell IJ, Kajdasz DK,
Walker DJ, Chappell AS: Estimation of minimum clinically important
difference for pain in fibromyalgia. Arthritis Care Res 2011, 63:821–826.
102. Beck AT, Steer RA, Carbin MG: Psychometric properties of the Beck
Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev
1988, 8:77–100.
103. Hiroe T, Kojima M, Yamamoto I, Nojima S, Kinoshita Y, Hashimoto N,
Watanabe N, Maeda T, Furukawa TA: Gradations of clinical severity and
sensitivity to change assessed with the Beck Depression Inventory-II in
Japanese patients with depression. Psychiatry Res 2005, 135:229–235.104. Bjelland I, Dahl AA, Haug TT, Neckelmann D: The validity of the Hospital
Anxiety and Depression Scale: An updated literature review. J Psychosom
Res 2002, 52:69–77.
105. Herrmann C: International experiences with the Hospital Anxiety and
Depression Scale-A review of validation data and clinical results.
J Psychosom Res 1997, 42:17–41.
106. Silverstone PH: Poor efficacy of the hospital anxiety and depression scale
in the diagnosis of major depressive disorder in both medical and
psychiatric patients. J Psychosom Res 1994, 38:441–450.
107. Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D: Validity,
reliability and responsiveness of the Work Productivity and Activity
Impairment Questionnaire in ankylosing spondylitis. Rheumatology
(Oxford) 2010, 49:812–819.
108. Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis A: Validity of the
work productivity and activity impairment questionnaire - general health
version in patients with rheumatoid arthritis [abstract]. Arthritis Res Ther
2010, 12:R177.
109. Tang R, Groshen SG, Piatek CI, Desai BB, Pinski JK, Acosta F, Raghavan D,
Dorff TB, Quinn DI: Sequential active chemotherapy schema in
castration-resistant prostate cancer [abstract]. J Clin Oncol 2011, 29:e15191.
110. Krupp L, LaRocca N, Muir-Nash J, Steinberg A: The fatigue severity scale:
Application to patients with multiple sclerosis and systemic lupus
erythematosus. Arch Neurol 1989, 46:1121–1123.
111. Mattsson M, Moller B, Lundberg IE, Gard G, Bostrom C: Reliability and
validity of the Fatigue Severity Scale in Swedish for patients with
systemic lupus erythematosus. Scand J Rheumatol 2008, 37:269–277.
112. Refolo P, Minacori R, Mele V, Sacchini D, Spagnolo AG: Patient-reported
outcomes (PROs): the significance of using humanistic measures in
clinical trial and clinical practice. Eur Rev Med Pharmacol Sci 2012,
16:1319–1323.
doi:10.1186/s12955-014-0116-1
Cite this article as: Holloway et al.: Patient-reported outcome measures
for systemic lupus erythematosus clinical trials: a review of content
validity, face validity and psychometric performance. Health and Quality
of Life Outcomes 2014 12:116.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
